Evidence map›Paper›PMID 39021298›Full record

ArticleCancer science2024

Discovering cancer stem-like molecule, nuclear factor I X, using spatial transcriptome in gastric cancer.

Akira Ishikawa, Takafumi Fukui, Aya Kido, Narutaka Katsuya, Kazuya Kuraoka, Naohiro Uraoka, Takahisa Suzuki, Shiro Oka, Takahiro Kotachi, Hassan Ashktorab and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Akira IshikawaDepartment of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-1528-1939
Takafumi FukuiDepartment of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Aya KidoDepartment of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Narutaka KatsuyaDepartment of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kazuya KuraokaDepartment of Diagnostic Pathology, National Hospital Organization (NHO), Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima, Japan.
Naohiro UraokaDepartment of Pathology, Kure Kyosai Hospital, Federation of National Public Services and Affiliated Personnel Mutual Aid Associations, Kure, Japan.
Takahisa SuzukiDepartment of Surgery, National Hospital Organization (NHO), Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima, Japan.
Shiro OkaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takahiro KotachiDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hassan AshktorabDepartment of Medicine and Cancer Center, Howard University College of Medicine, Washington, DC, USA.
Duane SmootDepartment of Medicine, Meharry Medical College, Nashville, Tennessee, USA.
Wataru YasuiDepartment of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-8647-8405

Funding

KAKENHI Grant-in-Aid for Early-Career Scientists JP21K15394KAKENHI Grant-in-Aid for Early-Career Scientists JP24K18398
6 · The paper itself

Abstract

Gastric cancer (GC) is characterized by significant intratumoral heterogeneity, and stem cells are promising therapeutic targets. Despite advancements in spatial transcriptome analyses, unexplored targets for addressing cancer stemness remain unknown. This study aimed to identify Nuclear Factor IX (NFIX) as a critical regulator of cancer stemness in GC and evaluate its clinicopathological significance and function. Spatial transcriptome analysis of GC was conducted. The correlation between NFIX expression, clinicopathological factors, and prognosis was assessed using immunostaining in 127 GC cases. Functional analyses of cancer cell lines validated these findings. Spatial transcriptome analysis stratified GC tissues based on genetic profiles, identified CSC-like cells, and further refined the classification to identify and highlight the significance of NFIX, as validated by Monocle 3 and CytoTRACE analyses. Knockdown experiments in cancer cell lines have demonstrated the involvement of NFIX in cancer cell proliferation and kinase activity. This study underscores the role of spatial transcriptome analysis in refining GC tissue classification and identifying therapeutic targets, highlighting NFIX as a pivotal factor. NFIX expression is correlated with poor prognosis and drives GC progression, suggesting its potential as a novel therapeutic target for personalized GC therapies.

Indexed as

Gene Expression Regulation, NeoplasticNeoplastic Stem CellsNFI Transcription FactorsStomach NeoplasmsTranscriptomeAgedBiomarkers, TumorCell Line, TumorCell ProliferationFemaleGene Expression ProfilingHumansMaleMiddle AgedPrognosisBiomarkers, TumorNFI Transcription Factorsbiomarkergastric cancergastric mucin phenotypenuclear factor IXspatial transcriptome

Identifiers

PMID39021298
PMCPMC11462935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.